Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.

OBJECTIVE Interleukin-21 (IL-21) is a T cell-derived cytokine that modulates T cell, B cell, and natural killer cell responses. In this study, the effects of blocking IL-21 were examined in 2 rodent models of rheumatoid arthritis (RA) to determine whether IL-21 contributes to their pathologic processes. METHODS DBA/1 mice were immunized with bovine type II collagen and then treated with murine IL-21 receptor Fc fusion protein (IL-21R.Fc), which was initiated after the onset of arthritis symptoms in 10% of the cohort. The mice were assessed 3 times per week for signs of disease, including histologic features as well as serum cytokine, Ig, and cytokine messenger RNA (mRNA) levels in the paws. In a separate experiment, Lewis rats were immunized with Freund's complete adjuvant followed by administration of IL-21R.Fc at the peak of inflammation in the joints. Rats were assessed daily for histologic features and for scoring of arthritis severity. In addition, the effects of IL-21R.Fc on the production of interferon-gamma (IFNgamma) by T cells were examined. RESULTS Treatment of DBA/1 mice with IL-21R.Fc reduced the clinical and histologic signs of collagen-induced arthritis. Nonspecific IgG1 levels were decreased in response to treatment. The levels of IL-6 mRNA in the paws and the serum IL-6 levels were decreased after treatment with IL-21R.Fc. IFNgamma mRNA levels were increased in the paws, and the addition of IL-21R.Fc to collagen-activated lymph node cultures enhanced the levels of IFNgamma. Collagen-specific spleen cell responses in IL-21R.Fc-treated mice were observed as reduced levels of IFNgamma and increased levels of IL-6. Treatment of Lewis rats with IL-21R.Fc after induction of adjuvant-induced arthritis resulted in reversal of disease signs and improvements in histologic parameters. CONCLUSION These findings demonstrate a pathogenic role for IL-21 in animal models of RA, and support consideration of IL-21 as a therapeutic target in human RA.

[1]  T. Ottenhoff,et al.  Divergent effects of IL‐12 and IL‐23 on the production of IL‐17 by human T cells , 2006, European journal of immunology.

[2]  M. Dougados,et al.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[3]  S. Nutt,et al.  Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer , 2005, The Journal of experimental medicine.

[4]  R. Colman,et al.  A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat , 2005, Arthritis research & therapy.

[5]  M. Follettie,et al.  The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-κB transcriptional activity in models of rheumatoid arthritis , 2005, Arthritis research & therapy.

[6]  Qingsheng Li,et al.  IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-211 , 2004, The Journal of Immunology.

[7]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[8]  F. Emmrich,et al.  Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[9]  L. Joosten,et al.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. , 2004, Arthritis and rheumatism.

[10]  W. Leonard,et al.  In vivo antitumor activity of interleukin 21 mediated by natural killer cells. , 2003, Cancer research.

[11]  T. Mcclanahan,et al.  Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation , 2003, The Journal of experimental medicine.

[12]  R. Paus,et al.  Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. , 2003, The Journal of investigative dermatology.

[13]  D. Foster,et al.  Interleukin-21 inhibits dendritic cell activation and maturation. , 2003, Blood.

[14]  A. Kang,et al.  Immunopathogenesis of Collagen Arthritis , 2003, Springer Seminars in Immunopathology.

[15]  M. Collins,et al.  IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN-γ1 , 2003, The Journal of Immunology.

[16]  W. van Eden,et al.  Immune regulation in adjuvant-induced arthritis: possible implications for innovative therapeutic strategies in arthritis. , 2003, Arthritis and rheumatism.

[17]  Takao Shimizu,et al.  Cytosolic Phospholipase A2α–deficient Mice Are Resistant to Collagen-induced Arthritis , 2003, The Journal of experimental medicine.

[18]  M. Collins,et al.  IL-21 and IL-21 receptor , 2003, Immunologic research.

[19]  A. Sher,et al.  A Critical Role for IL-21 in Regulating Immunoglobulin Production , 2002, Science.

[20]  J. Parrish-Novak,et al.  Interleukin‐21 and the IL‐21 receptor: novel effectors of NK and T cell responses , 2002, Journal of leukocyte biology.

[21]  A. Satoskar,et al.  Interleukin 21 Is a T Helper (Th) Cell 2 Cytokine that Specifically Inhibits the Differentiation of Naive Th Cells into Interferon γ–producing Th1 Cells , 2002, The Journal of experimental medicine.

[22]  K. Weinberg,et al.  The Common γ Chain (γc) Is a Required Signaling Component of the IL-21 Receptor and Supports IL-21-Induced Cell Proliferation via JAK3† , 2002 .

[23]  M. Collins,et al.  IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. , 2002, Immunity.

[24]  R. Holmdahl,et al.  The molecular pathogenesis of collagen-induced arthritis in mice—a model for rheumatoid arthritis , 2002, Ageing Research Reviews.

[25]  R. Holmdahl,et al.  Arthritis induced in rats with non‐immunogenic adjuvants as models for rheumatoid arthritis , 2001, Immunological reviews.

[26]  W. B. van den Berg,et al.  Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. , 2001, Arthritis and rheumatism.

[27]  H. Asao,et al.  Cutting Edge: The Common γ-Chain Is an Indispensable Subunit of the IL-21 Receptor Complex1 , 2001, The Journal of Immunology.

[28]  Scott R. Presnell,et al.  Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function , 2000, Nature.

[29]  W. Leonard,et al.  Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Y. Saeki,et al.  Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. , 1999, Arthritis and rheumatism.

[31]  T. Kishimoto,et al.  Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. , 1998, Arthritis and rheumatism.

[32]  R. Holmdahl,et al.  B cell‐deficient mice do not develop type II collagen‐induced arthritis (CIA) , 1998, Clinical and experimental immunology.

[33]  G. Kollias,et al.  Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.

[34]  A. Billiau,et al.  Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. , 1997, Journal of immunology.

[35]  W. Lesslauer,et al.  Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. , 1996, Journal of immunology.

[36]  P. Nickerson,et al.  Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. , 1995, Journal of immunology.

[37]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Kang,et al.  Induction of arthritis with monoclonal antibodies to collagen. , 1992, Journal of immunology.

[39]  R. Kaufman.  Selection and coamplification of heterologous genes in mammalian cells. , 1990, Methods in enzymology.

[40]  R. Kaufman.  Vectors used for expression in mammalian cells. , 1990, Methods in enzymology.

[41]  H. Mcdevitt,et al.  Heterogeneous effects of IFN-gamma in adjuvant arthritis. , 1989, Journal of immunology.

[42]  A. Poole,et al.  Rheumatoid-like joint lesions in rabbits injected intravenously with bovine serum. , 1977, International archives of allergy and applied immunology.

[43]  H. Dorfman,et al.  Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. , 1971, The Journal of bone and joint surgery. American volume.